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SUMMARY STATEMENT 
This study demonstrates the utility of a transgenic mouse model of breast cancer to 
define mechanisms of resistance to a pan-HER family inhibitor and identifies a link 
with EMT.  
 
ABSTRACT 
Resistance to HER2 targeted therapies presents a major clinical problem. Although 
preclinical studies have identified a number of possible mechanisms clinical 
validation has been difficult. This most likely reflects the reliance on cell line models 
that do not recapitulate the complexity and heterogeneity seen in human tumours. 
Here we show the utility of a genetically engineered mouse model of HER2 driven 
breast cancer (MMTV-NIC) to define mechanisms of resistance to the pan-HER 
family inhibitor AZD8931. Genetic manipulation of MMTV-NIC mice demonstrated 
that loss of PTEN conferred de novo resistance to AZD8931, while a tumour 
fragment transplantation model was established to assess mechanisms of acquired 
resistance. Using this approach 50% of tumours developed resistance to AZD8931. 
Analysis of the resistant tumours showed two distinct patterns of resistance: tumours 
in which reduced membranous HER2 expression was associated with an epithelial-to-
mesenchymal transition (EMT) and resistant tumours that retained HER2 expression 
and an epithelial morphology. The plasticity of the EMT phenotype was demonstrated 
upon re-implantation of resistant tumours that then showed a mixed epithelial and 
mesenchymal phenotype. Further AZD8931 treatment resulted in the generation of 
secondary resistant tumours that again had either undergone EMT or had retained 
their original epithelial morphology. The data provide a strong rationale for basing 
therapeutic decisions on the biology of the individual resistant tumour, which may be 
very different from that of the primary tumour and will be specific to individual 
patients.  
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INTRODUCTION 
HER2 (human epidermal growth factor receptor 2) gene amplification and/or protein 
overexpression occurs in around 20% of breast cancers and is associated with poor 
prognosis. Several drugs capable of specifically targeting the HER2 pathway have 
been developed for use in both early and late HER2-positive disease and have had a 
significant impact on the treatment of HER2-positive breast cancer (Arteaga et al, 
2012). These include antibodies directed against HER2 including trastuzumab and 
pertuzumab, and also small molecule tyrosine kinase inhibitors that target the kinase 
activity of HER2 and HER1 such as lapatinib. Although initial response rates to the 
current HER2-targeted therapies are good, resistance is inevitable. Further tyrosine 
kinase inhibitors including AZD8931 (sapatinib) and neratinib have been developed 
in an attempt to improve efficacy rates and duration of response. Preclinical studies 
have identified numerous mechanisms of both de novo and acquired resistance 
(Creedon et al, 2014; Rexer & Arteaga, 2012) although their clinical validation has 
been more difficult which reflects the inability of the conventional cell based 
approaches to adequately model the complexity of the human disease.  
The limitation of conventional cell culture and mouse xenograft studies is well 
recognized as an obstacle to the effective translation of preclinical findings into 
clinical benefit (Sharpless & Depinho, 2006). Use of genetically engineered models in 
which tumours develop in situ in the context of an intact microenvironment is a viable 
alternative for preclinical assessment of both drug response and mechanisms of 
resistance (van Miltenburg & Jonkers, 2012). Generation of autochthonous tumours 
driven by cell specific expression of oncogenic drivers or loss of tumour suppressors 
relevant to human tumours gives rise to tumours in which the histopathology and 
disease progression also recapitulate many aspects of the human disease providing 
more relevant models with which to study drug response. Here we describe the use of 
a HER2 driven model of mammary tumourigenesis as a preclinical tool to study 
response and resistance mechanisms in HER2-positive breast cancer. We have used 
the MMTV-NIC (Neu-IRES-Cre) model (Ursini-Siegel et al, 2008), which employs a 
bicistronic transcript to co-express activated ErbB2/Neu (HER2) with MMTV-Cre 
recombinase, resulting in the formation of activated ErbB2/Neu driven mammary 
tumours. The advantage of this model is that the coupling of activated ErbB2/Neu 
with Cre recombinase in the same cell means that Cre negative tumour cells are not 
generated allowing the efficient Cre-mediated deletion of additional conditional 
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alleles (Schade et al, 2009). This allows validation of potential mechanisms of de 
novo resistance such as loss of PTEN. Loss of PTEN and subsequent activation of the 
PI3K pathway has been identified as a key determinant of trastuzumab sensitivity and 
has been associated with poorer overall survival in trastuzumab treated patients 
(Berns et al, 2007; Esteva et al, 2010; Nagata et al, 2004) although the impact on 
lapatinib resistance remains unclear (Xia et al, 2007). Here we have coupled loss of 
PTEN with HER2 activation in the MMTV-NIC model and demonstrate that loss of 
PTEN is associated with de novo resistance to the small molecule tyrosine kinase 
inhibitor sapatinib (AZD8931). We also show the utility of the model for identifying 
mechanisms of acquired resistance to HER2 targeted therapy and identify the 
induction of an epithelial-to-mesenchymal transition (EMT) in a sub-population of 
AZD8931 resistant tumours. 
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RESULTS  
Loss of PTEN confers resistance to AZD8931 
Initial experiments were carried out to determine whether the MMTV-NIC model was 
sensitive to the HER family tyrosine kinase inhibitor AZD8931. As loss of PTEN and 
activation of the PI3K signaling pathway has previously been reported to confer 
resistance to trastuzumab, cohorts of both MMTV-NIC PTEN+/+ and MMTV-NIC 
PTEN+/- mice were used. Both MMTV-NIC PTEN+/+ and MMTV-NIC PTEN+/- mice 
developed on average 4 tumours per mouse with 100% penetrance. As described 
previously, loss of PTEN accelerated tumour onset in the MMTV-NIC mice (Schade 
et al, 2009). The median age of tumour onset was 102 days in the MMTV-NIC 
PTEN+/- cohort compared to 150 days in the MMTV-NIC PTEN+/+ cohort (p=0.0001, 
Gehan-Breslow-Wilcoxon test)(Supplementary Fig. 1A). Western blot analysis of 
tumours showed reduced expression of PTEN and increased phosphorylation of Akt 
in tumours taken from the MMTV-NIC PTEN+/- mice consistent with increased 
signaling through the PI3K pathway (Supplementary Fig. 1B). 
To assess the response to AZD8931, we randomized cohorts of MMTV-NIC 
PTEN+/+ and MMTV-NIC PTEN+/- mice to treatment with either AZD8931 or vehicle. 
Median survival in the vehicle arm of the MMTV-NIC PTEN+/+ cohort following the 
start of treatment was 35 days (range 10-39 days), compared with 18 days (range 11-
24 days) in vehicle treated MMTV-NIC PTEN+/- mice. Drug treatment was stopped at 
40 days when all vehicle treated animals were sacrificed due to tumour burden. At 
this time none of the drug treated animals had to be sacrificed due to tumour burden 
(Fig. 1A and B). When we looked at the growth of the individual index tumours 
(defined as the largest tumour at the time of sacrifice) in the different cohorts after 40 
days, we saw that all AZD8931 treated MMTV-NIC PTEN+/+ tumours initially 
responded to treatment and 2 out of 5 tumours fully resolved. The growth of a further 
2 tumours was inhibited while the final tumour initially responded but after 17 days of 
drug treatment became insensitive and after 40 days of treatment, its volume had 
increased by 134.2%. By comparison, the tumours in the vehicle treated arm 
continued to grow throughout the experiment and the median percentage change in 
tumour volume was an increase of 294.6% (Fig. 1C). By contrast, all but 1 of 5 
AZD8931 treated MMTV-NIC PTEN+/- tumours became rapidly insensitive to 
AZD8931 and by day 40 all AZD8931 treated tumours had grown beyond their initial 
starting volume with a median percentage change in tumour volume of 131.1%. As 
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expected, all vehicle-treated tumours continued to grow steadily throughout the 
experiment with a median percentage change in tumour volume of 415.1% (Fig. 1D). 
In summary, AZD8931 resulted in tumour shrinkage in the majority of MMTV-NIC 
PTEN+/+ animals but whilst it slowed tumour growth in MMTV-NIC PTEN+/- animals 
it did not cause tumour resolution. We also noted that by day 40 there were fewer 
additional tumours in both the MMTV-NIC PTEN+/+ and MMTV-NIC PTEN+/- 
animals treated with AZD8931 and although this did not reach statistical significance 
the reduction in tumour burden was greater in the MMTV-NIC PTEN+/+ mice, 
consistent with the increased sensitivity of the MMTV-NIC PTEN+/+ tumours to 
AZD8931 (median values for tumours per mouse were: MMTV-NIC PTEN+/+, 
vehicle=5; MMTV-NIC PTEN+/+, AZD8931=1; MMTV-NIC PTEN+/-, vehicle=6; 
MMTV-NIC PTEN+/-, AZD8931=3, p=0.1025, Kruskal-Wallis). This illustrates the 
significant heterogeneity in response to AZD8931 between the two different cohorts 
and demonstrates that loss of PTEN leading to activation of the PI3K pathway confers 
de novo resistance to AZD8931.  
As there was little residual tissue from the AZD8931 treated MMTV-NIC PTEN+/+ 
animals at the completion of the experiment, additional cohorts of both MMTV-NIC 
PTEN+/+ and MMTV-NIC PTEN+/- mice were treated with vehicle or AZD8931 for 3 
days and effects on HER family signaling pathways assessed. There was a reduction 
in phosphorylation of HER2 and HER3 in MMTV-NIC PTEN+/+ and MMTV-NIC 
PTEN+/- tumours following treatment with AZD8931 compared to vehicle treated 
animals although this did not reach statistical significance following histoscoring (Fig. 
1E). This reflects the heterogenous expression and activation of both HER2 and 
HER3 in the tumours (Supplementary Fig. 1C). No significant EGFR (HER1) 
expression was detected in the MMTV-NIC tumours so it was not possible to assess 
effects on EGFR activation (results not shown). We used reverse phase protein arrays 
to look at downstream signaling to Akt, MAPK and S6 in the AZD8931 treated 
tumours and found that their activation was significantly inhibited in MMTV-NIC 
PTEN+/+ and MMTV-NIC PTEN+/- tumours (Fig. 1F). Immunohistochemical analysis 
showed that pAkt was confined to the tumour cells and not expressed in the 
surrounding stroma, while pMAPK was also expressed in the stroma and the reduced 
expression of pMAPK may therefore also reflect reduced activation of MAPK in the 
surrounding stroma (Supplementary Fig. 1D). Thus short-term treatment with 
AZD8931 treatment inhibits HER family signaling in both tumour types and the 
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differential response of the MMTV-NIC PTEN+/+ and MMTV-NIC PTEN+/- tumours 
does therefore not reflect an inability of the drug to inhibit the target in the different 
tumours.  
 
Establishment of orthotopic transplanted tumours 
The multifocal nature of the MMTV-NIC model means that it is not possible to study 
mechanisms of acquired drug resistance. We therefore established whether the 
MMTV-NIC PTEN tumours could be orthotopically transplanted into syngeneic wild 
type FVB/N mice to provide a more tractable model for drug resistance studies. We 
were able to establish tumours following transplantation of tumour fragments from 
MMTV-NIC PTEN+/- tumours but not from MMTV-NIC PTEN+/+ tumour fragments. 
Examination of H&E sections from the fragment derived MMTV-NIC PTEN+/- 
tumours confirmed the presence of highly mitotic, grade 3 carcinomas, which were 
indistinguishable from tumours that developed in the parental MMTV-NIC PTEN+/- 
model (Fig. 2A). Both parental and fragment derived tumours demonstrated inter-and 
intra-tumoural heterogeneity in HER2 expression (Fig. 2B) and consistent with the 
frequent observation of mitotic figures on H&E sections, a high percentage of nuclei 
stained positively for Ki67 in both parental and fragment derived tumours (Fig. 2C). 
The orthotopic transplantation model therefore provides a useful tool by 
circumventing problems associated with the multifocal nature of the genetically 
engineered model. 
Initial studies to determine the suitability of the MMTV-NIC transplantation model 
for drug efficacy studies were carried out using the taxane paclitaxel whose role in the 
management of both early and metastatic breast cancer is well established (Gajria et 
al, 2010; Ghersi et al, 2005). Paclitaxel treatment resulted in a statistically significant 
increase in overall survival of mice bearing fragment-derived tumours. Median 
overall survival was increased from 14 days in vehicle treated animals (range 7-14 
days) to 24 days (range 24-24 days) in drug treated animals (p=0.03, Gehan-Breslow 
Wilcoxon test). Looking at the response of individual tumours to treatment, we found 
that although paclitaxel slowed tumour growth, it did not result in tumour shrinkage 
(Fig. 2D).  
  
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
Development of resistance to AZD8931 
We next determined whether the MMTV-NIC tumours could be used to model 
acquired resistance to AZD8931. We generated tumour fragments from 3 separate 
MMTV-NIC PTEN+/- donor mice. From each, donor tumour fragments were then 
transplanted into cohorts of 6 wild type FVB/N mice. Following the development of 
established tumours, mice were randomized to treatment with either vehicle (n=3) or 
AZD8931 (n=3). AZD8931 treatment resulted in an initial inhibition of tumour 
growth in all mice. When tumours had regressed to ≤ 0.1cm3, AZD8931 treatment 
was stopped: following the subsequent regrowth of the tumour, treatment was then re-
started when tumours reached ≥ 0.3 cm3. This cycle was repeated until tumours either 
resolved or became resistant where they were able to continue growing in the 
presence of ongoing treatment. The resistant tumours originated from different donors 
and the treatment duration required for the individual tumours to become resistant 
varied between individual tumours (Fig. 3A).  
Histopathological examination of the matched AZD8931 naïve and resistant 
tumours revealed that although all the AZD8931 naïve tumours were histologically 
indistinguishable from each other (Fig. 3B, C) there were significant differences in 
the AZD8931 resistant tumours (Fig. 3D, E). While some of the resistant tumours had 
the same histopathological phenotype as their matched naïve tumour (Fig. 3D), a sub-
set of resistant tumours had a more pleomorphic appearance and were comprised of 
spindle cells suggestive of tumours under going EMT (Fig. 3E). 
Loss of cell surface E-cadherin is an established marker of EMT and while strong 
membranous expression of E-cadherin was seen in all drug naïve tumours, loss of E-
cadherin in the resistant tumours was associated with the conversion to a spindle cell 
morphology (Fig. 4A-D), with the resistant tumours that had not undergone the 
morphological change retaining expression of E-cadherin (Fig. 4I-L). This loss of E-
cadherin was accompanied by expression of the mesenchymal marker vimentin in the 
resistant spindle cell tumours (Fig. 4E, F) indicating that these resistant tumours have 
undergone EMT. HER2 expression was preserved in the resistant tumours which had 
retained the histopathological features of the drug naïve tumours (Fig. 4O, P), but 
total loss of membranous HER2 expression was seen in the resistant spindle cell 
tumours (Fig. 4G, H). 
To establish whether the resistant phenotype was stable, fragments from one 
individual resistant tumour were reimplanted into cohorts of wild type FVB/N mice. 
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Following the development of established tumours, mice were randomized to 
treatment with either vehicle or AZD8931. AZD8931 treatment prevented the growth 
of one tumour, although tumour regression did not occur (Fig. 5A, red growth curve, 
“AZD8931 responsive”). The remaining three tumours responded initially to 
AZD8931, although resistance did develop over time (Fig. 5A, black growth curves, 
“AZD8931 resistant”). The onset of secondary resistance was faster than in the 
orginal drug naïve tumour fragments (compare Figs 3A, 5A).  
The vehicle treated tumours were all highly mitotic with rounded cells with 
pleomorphic nuclei (Fig. 5B). The tumour whose growth was inhibited by AZD8931 
had mild to moderately pleomorphic nuclei and no mitoses (Fig. 5C). The resistant 
tumours had distinct morphologies: two of the tumours were comprised of highly 
mitotic spindle cells with similar histology to those seen in the primary resistant 
tumours that had undergone EMT (compare Fig. 5E, F and Fig. 3C), while the 
remaining resistant tumour had a papillary architecture with moderate/marked nuclear 
pleomorphism (Fig. 5D). As we had previously demonstrated a reduction in pAkt and 
pMAPK following acute treatment with AZD8931 (Fig. 1F) we looked at activation 
of Akt and MAPK following development of resistance to AZD8931 (Fig. 6G-P). 
Chronic exposure to AZD8931 did not reduce pAkt and pMAPK levels, although one 
AZD89231 resistant tumour showed an overall reduction in pMAPK staining with 
only small pockets of pMAPK positive cells scattered throughout the tumour (Fig. 
6N). 
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Further analysis of the tumours revealed that all vehicle treated tumours expressed 
both E-cadherin and vimentin (Fig. 6A). The AZD8931 responsive tumour was also 
both E-cadherin and vimentin positive although the number of vimentin positive 
tumour cells was much lower than in the vehicle treated tumours (Fig. 6B). As with 
the primary resistant tumours the two spindle cell AZD8931 resistant tumours had 
lost E-cadherin and were strongly vimentin positive. Strikingly this was associated 
with loss of membranous HER2 expression (Fig. 6D, E). The remaining AZD8931 
resistant tumour resembled the vehicle treated tumours being both E-cadherin and 
vimentin positive (Fig. 6C). Thus the development of resistance to AZD8931 in a sub-
population of tumours is linked to increased expression of markers associated with the 
induction of EMT and loss of membranous HER2. To further explore the mechanisms 
of EMT induction in the resistant tumours we looked at expression of Zeb1 which is a 
known transcriptional regulator of EMT. Upregulation of nuclear Zeb1 was only seen 
in the resistant spindle cell tumours consitent with a Zeb1 regulated induction of EMT 
(Fig. 7).  
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DISCUSSION 
It is widely acknowledged that the use of conventional xenograft models for 
preclinical drug testing has limited predictive clinical value. Use of genetically 
engineered mouse models provides a useful alternative in which drug response and 
resistance can be evaluated in situations that more faithfully recapitulate the human 
disease (Olive et al, 2009; Singh et al, 2010; Wang et al, 2012). Here we show that the 
MMTV-NIC model has utility in assessing efficacy and resistance mechanisms of 
HER2 targeted therapies. Comparison of tumours with the same genotype 
demonstrated heterogeneity in the rate and extent of response to AZD8931, despite 
the use of predefined genetic mutations to drive tumour development. This variation 
in therapeutic response has been previously described in other genetically engineered 
models (Rottenberg et al, 2007) and contrasts with the more uniform response seen in 
xenograft studies (Becher & Holland, 2006). This is an important advance as it 
enables us to more accurately recapitulate the behaviour of human tumours and is 
most likely due to the random acquisition of secondary mutations during tumour 
development and progression in these models. In addition we show for the first time 
that acquired resistance to a HER2 targeted therapy can be modeled in MMTV-NIC 
tumours. The majority of studies exploring resistance to HER2 directed therapies 
have used cell line based approaches and although numerous resistance mechanisms 
have been identified in vitro, clinical validation has proved challenging. The use of 
genetically engineered models to explore resistance mechanisms offers a more 
physiologically relevant system with tumours developing resistance whilst exposed to 
ongoing in vivo selection pressures. Therefore any resistance strategies identified may 
be more predictive of clinically relevant resistance mechanisms.  
 
We identified PTEN loss as an important determinant of de novo AZD8931 
resistance. Loss of PTEN and subsequent activation of the PI3K pathway has been 
identified as a key determinant of trastuzumab sensitivity and has been associated 
with poorer overall survival in trastuzumab treated patients (Berns et al, 2007; Esteva 
et al, 2010; Nagata et al, 2004) although the impact on lapatinib resistance remains 
unclear (Xia et al, 2007). Like lapatinib, AZD8931 is a dual inhibitor of both HER2 
and HER1, however, it has a unique profile of activity being a more effective 
inhibitor of HER family signaling than lapatinib resulting in a distinct profile of anti-
tumour activity (Hickinson et al, 2010). Current trials are underway to determine 
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whether the more effective simultaneous inhibition of HER family signaling provided 
by AZD8931 could have clinical benefit (Tjulandin et al, 2013), and thus 
understanding potential mechanisms of resistance to AZD8931 is required. Both 
MMTV-NIC PTEN+/+ and MMTV-NIC PTEN+/- tumours displayed reduced Akt 
activity following treatment with AZD8931, although in both models there was still 
evidence of residual activity following AZD8931 treatment. Incomplete inhibition of 
Akt signaling is a well-established mechanism of resistance to HER2 targeted 
therapies (Rexer & Arteaga, 2012) and is likely to contribute to the continued tumour 
progression in the MMTV-NIC PTEN+/- model. In support of this we saw no 
reduction in pAkt in AZD8931 MMTV-NIC PTEN+/- resistant tumours following 
chronic drug treatment. Other studies have shown that combination therapy using a 
HER2 monoclonal antibody and an Akt inhibitor inhibited growth of MMTV-NIC 
PTEN-/- tumours, which were resistant to treatment with either drug alone (Wang et 
al, 2012). Taken together this supports the use of Akt inhibitors in combination with 
HER2 targeted therapies and a number of clinical trials are currently underway to 
evaluate the use of trastuzumab and/or lapatinib with Akt inhibitors. 
One of the major advantages of using the MMTV-NIC tumours for modeling drug 
resistance was the generation of resistant tumours with distinct molecular phenotypes, 
which recapitulates in part the heterogeneity seen in the clinic. This provides a strong 
rationale for basing therapeutic decisions on the biology of the individual resistant 
tumour, which may be very different from that of the primary tumour. For example, 
the observation that a sub-set of our resistant tumours no longer expressed high levels 
of membranous HER2 could have a significant impact on future treatments. To date, 
major advances in overcoming clinical resistance to trastuzumab have focused on 
alternative strategies for targeting HER2 signaling, either through combining drugs 
which target different HER family receptors or through use of drug-antibody 
conjugates such as trastuzumab-emtansine. As it is rarely mandatory to re-biopsy 
tumours at the time of entry into clinical trials, patients whose tumours no longer 
express HER2 risk being exposed to the toxicity of treatments that might not be 
anticipated to be effective.  
Several in vitro studies have shown that resistance to lapatinib and trastuzumab are 
associated with induction of EMT (Creedon et al, 2014; Kim et al, 2013; Korkaya et 
al, 2012; Oliveras-Ferraros et al, 2012) and our finding that a sub-set of the resistant 
tumours have undergone EMT indicates that targeting pathways that regulate EMT 
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may be effective in a sub-population of resistant tumours (Singh & Settleman, 2010). 
Interestingly the generation of mixed vimentin and E-cadherin positive tumours 
following re-implantation of an AZD8931 resistant tumour shows that the induction 
of EMT is not binary and that the tumours are highly plastic and can respond to 
microenvironmental factors that can affect their EMT status. The initial response of 
the re-implanted resistant tumour fragments to AZD8931 most likely reflects this 
plasticity with the reversion to a more epithelial phenotype and the concomitant re-
expression of HER2 conferring initial drug sensitivity. Although we have shown that 
the induction of EMT is associated with acquired resistance to AZD8931, induction of 
EMT in HER2-driven mouse mammary tumours via expression of an activating PI3K 
mutation was associated with de novo resistance to HER2 targeted therapies (Hanker 
et al, 2013) while in vitro studies showed that expression of transcription factors that 
drive EMT was causally related to de novo trastuzumab resistance (Oliveras-Ferraros 
et al, 2012).  
One of the main challenges going forward is the identification of effective drug 
combinations to combat resistance to HER2 targeted therapies. Use of the 
transplantable tumour model described here provides a powerful preclinical tool with 
which to test potential novel combinations in resistant tumours, studies which to date 
rely on use of resistant cell lines established in vitro. For example, exploiting the 
molecular differences in resistant tumours that have undergone EMT may provide 
alternative combination strategies for overcoming resistance in these tumours. 
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MATERIALS AND METHODS 
Animals 
MMTV-NIC mice expressing an oncogenic ErbB2/Neu allele and Cre recombinase 
under the control of the MMTV promoter were generated as previously described 
(Ursini-Siegel et al, 2008) and inter-crossed with floxed Pten (strain C;129S4-
Ptentm1Hwu/J, Jackson Laboratory) mice to generate either MMTV-NIC PTEN+/+ or 
MMTV-NIC PTEN+/- progeny on a FVB/N background. Genotyping was carried out 
by Transnetyx (Cordova, TN, USA). All experiments were conducted in compliance 
with UK Home Office guidelines. Nulliparous females were monitored twice weekly, 
using manual palpation, for tumour formation. The greatest tumour dimension and its 
perpendicular measurement were recorded and once tumours had reached their 
maximum size (1.5 cm in one direction) as determined by Home Office regulations, 
mice were sacrificed. Tumours were then collected and fixed in 10% neutral buffered 
formalin. Tumours used for the generation of fragments were washed in ice cold PBS 
and cut into 1 mm3 fragments and any macroscopic necrotic areas removed and then 
centrifuged at 450g for 1 minute. The supernatant, containing fibrous and necrotic 
material, was removed and the remaining fragments suspended in cryopreservation 
buffer (50% DMEM, 45% foetal bovine serum, 5% DMSO) and stored at -800C. At 
the time of transplantation, fragments were defrosted at room temperature, washed in 
PBS and inserted into the fourth mammary fat pad.  
For drug studies using AZD8931 (AstraZeneca Oncology iMed, Alderley Park, 
UK) treatment was commenced when mice had at least 1 tumour ≥ 0.1 cm3 (index 
tumour) and continued until complete resolution of the index tumour or until the 
animal was sacrificed due to tumour size ≥ 1.5 cm (in any direction). Mice were 
dosed daily with vehicle 1% Tween 80 (in PBS) or AZD8931 (100 mg/kg) suspended 
in 1% Tween 80 (in PBS) by oral gavage. To generate tumours that were resistant to 
AZD8931 an intermittent drug treatment schedule was performed. Following 
transplantation of tumour fragments tumours were allowed to grow to ≥ 0.1 cm3 
before treatment with AZD8931 as above was started. When tumours regressed to < 
0.1 cm3, AZD8931 treatment was stopped and tumours monitored twice weekly. If the 
tumour regrew treatment was then re-started when tumours reached ≥ 0.3 cm3. This 
cycle was repeated until tumours developed resistance and were sacrificed when the 
maximum tumour size (1.5 cm in any direction) was reached as permitted under UK 
Home Office regulations. For drug studies using paclitaxel, treatment was 
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commenced when mice had at least 1 tumour ≥ 0.15 cm3 (index tumour) and 
continued until the animal was sacrificed due to tumour size or when the experiment 
was terminated 72 hours after the fourth dose of paclitaxel. Mice were dosed weekly 
with vehicle (cremaphor EL:ethanol, 1:1, v:v) or paclitaxel (10 mg/kg) suspended in 
cremaphor EL:ethanol by intraperitoneal injection.  
 
Immunohistochemistry 
Immunohistochemistry of formalin-fixed, paraffin-embedded tissues was performed 
as described previously (Karim et al, 2013). Primary antibodies used were HER2 
(Invitrogen, Cat#AHO1011, 1:1000), pY1221/1222 HER2 (Cat#2243, 1:400), 
pY1289 HER3 (Cat#4791, 1:100), Ki67 (Vector, Cat#VP-RM04, 1:500), E-cadherin 
(Cat#3195, 1:5000), vimentin (Cat#5741, 1:100), pS473 Akt (Cat#4060, 1:50) and 
pT202/Y204 MAPK (Cat#4370, 1:400)(all Cell Signaling, UK).  
 
Western blotting 
Western blot analysis was performed as described previously (Karim et al, 2013). 
Primary antibodies used were HER2 (Cat#2248, 1:1000), pS473 Akt (Cat#4060, 
1:1000), Akt (Cat#9272, 1:1000), PTEN (Cat#9552, 1:1000) and (all Cell Signaling, 
UK) and -actin (Cat#A4700, Sigma, UK; 1:5000). 
 
Reverse phase protein array (RPPA) analysis 
Tumours were washed with PBS and lysed in 1% Triton X-100, 50 mM HEPES (pH 
7.4), 150 mM sodium chloride, 1.5 mM magnesium chloride, 1 mM EGTA, 100 mM 
sodium fluoride, 10 mM sodium pyrophosphate, 1 mM sodium vanadate, 10% 
glycerol, supplemented with cOmplete ULTRA protease inhibitor and PhosSTOP 
phosphatase inhibitor cocktails (Sigma, UK). Cleared lysates were serially diluted to 
produce a dilution series comprising four serial two-fold dilutions of each sample, 
which were spotted onto nitrocellulose-coated slides (Grace Bio-Labs, supplied by 
Sigma, UK) in triplicate under conditions of constant 70% humidity using the Aushon 
2470 array platform (Aushon Biosystems, Billerica, MA, USA). Slides were hydrated 
in blocking buffer (Thermo Fisher Scientific, UK) and then incubated with primary 
antibodies (all 1:250 from Cell Signaling, UK). Bound antibodies were detected by 
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incubation with anti-rabbit DyLight 800-conjugated secondary antibody (New 
England BioLabs, UK). An InnoScan 710-IR scanner (Innopsys, Carbonne, France) 
was used to read the slides, and images were acquired at the highest gain without 
saturation of the fluorescence signal. The relative fluorescence intensity of each 
sample replicate was quantified using Mapix software (Innopsys). 
The linear fit of the dilution series of each sample was determined for each primary 
antibody, from which median relative fluorescence intensities were calculated, and 
samples with R2 < 0.8 in all three replicates were excluded. Signal intensities were 
normalized by global sample median normalization (Guo et al, 2012).  
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Figures 
 
 
 
 
Fig. 1: PTEN status determines the sensitivity to AZD8931. Cohorts of MMTV-
NIC-PTEN+/+ and NIC-PTEN+/- mice were randomized to treatment with daily 
AZD8931 or vehicle and tumour response monitored. (A) Overall survival in vehicle 
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(n=5) and AZD8931 (n=5) treated NIC-PTEN+/+ mice (p=0.0043, Gehan-Breslow 
Wilcoxon test).  (B) Overall survival in vehicle (n=5) and AZD8931 (n=5) treated 
NIC-PTEN+/- mice (p=0.0039, Gehan-Breslow Wilcoxon test). (C) Waterfall plot of 
percentage tumour volume change over duration of experiment in NIC-PTEN+/+ 
vehicle and AZD8931 treated animals (p=0.0079, Mann Whitney U test). (D) 
Waterfall plot of percentage tumour volume change over duration of experiment in 
NIC-PTEN+/- vehicle and AZD8931 treated animals (p=0.0079, Mann Whitney U 
test). Vehicle treated mice were sacrificed when tumour burden reached maximum 
permitted size: 10-39 days for MMTV-NIC PTEN+/+ mice) and 11-24 days for 
MMTV-NIC PTEN+/- mice. AZD8931 treatment was stopped at 40 days when all 
vehicle treated animals were sacrificed due to tumour burden. (E) 
Immunohistochemical analysis was performed on paraffin embedded sections of 
AZD8931 and vehicle treated tumours with pTyr 1221/1222 HER2 and pTyr 1289 
HER3 antibodies. Membranous histoscore calculated as the sum of the product of 
percentage cells stained by the intensity graded from 0-3, where 1=weak, 2=moderate 
and 3=strong staining (histoscore = (% *1) + (% *2) + (% *3)). pTyr 1221/1222 
HER2 staining NIC-PTEN+/+: p=0.48, NIC-PTEN+/-: p=1.0 and pTyr1289 HER3 
staining NIC-PTEN+/+: p=0.20, NIC-PTEN+/-: p=0.07 Mann-Whitney U test 
comparing vehicle and AZD8931 treated tumours. Black data points represent vehicle 
treated tumours. Red data points represent AZD8931 treated tumours. Bar represent 
mean value for each genotype. (F) Reverse phase protein array analysis was 
performed on lysate from AZD8931 (red data points) and vehicle (black data points) 
treated NIC-PTEN+/+ and NIC-PTEN+/- tumours. The ratio of phospho:total protein 
RFI value is presented and normalized to the maximum value in each data set. 
*p≤0.05 and **p≤0.01 comparing vehicle and AZD8931 for each antibody, Mann 
Whitney U test.  
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Fig. 2: Transplantation of NIC-PTEN+/- fragments generated tumours that were 
indistinguishable from the parental tumours. (A) Representative H&E images of 
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fragment derived and spontaneous tumours from NIC-PTEN+/- mice. Mag x20. (B) 
Representative images of HER2 and (C) Ki67 expression in fragment derived and 
spontaneous tumours. Mag x20, scale bar 100 m. (D) Growth rate of vehicle (n=3) 
and paclitaxel (n=3) treated fragment derived tumours. 
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Fig. 3: Generation of fragment derived tumours with acquired resistance to 
AZD8931. (A) Representative growth curves of 3 independent NIC-PTEN+/- tumour 
fragments treated with AZD8931. Repeated cycles of AZD8931 were administered to 
facilitate the selection of tumours with acquired resistance to AZD8931. Green 
arrowheads indicate the start of treatment and red arrowheads indicate when treatment 
was stopped. (B, C) Representative H&E images of AZD8931 naïve (vehicle) and 
resistant tumours. (D) AZD8931 resistant tumour phenotypically indistinguishable 
from AZD8931 naive tumour. (E) AZD8931 resistant tumours consisted of spindle 
shaped cells. Mag x20, scale bar 100 m. 
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Fig. 4: AZD8931 resistance is associated with EMT in a sub-population of 
tumours. Analysis of AZD8931 naive (vehicle) and resistant tumours showing 
representative images of H&E staining and immunohistochemical analysis of E-
cadherin, vimentin and HER2. Mag x20, scale bar 50 m. (A-H) AZD8931 resistant 
spindle cell tumour and corresponding vehicle treated tumour. (I-P) AZD8931 
resistant tumour phenotypically indistinguishable from AZD8931 naïve (vehicle) 
tumour and corresponding vehicle treated tumour.  
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Fig. 5: Generation of secondary resistance in NIC-PTEN+/- tumour fragments. 
(A) Growth curves of NIC-PTEN+/- AZD8931 resistant tumour fragments following 
treatment with repeated cycles of AZD8931. Black lines represent tumours that 
developed resistance to AZD8931. Red line represents tumour whose growth was 
inhibited by AZD8931. Treatment was stopped after 90 days due to lack of tumour 
growth. (B) Representative H&E staining of vehicle treated tumours. (C-F) H&E 
staining of AZD8931 treated tumours: (C) shows AZD8931 responsive tumour (red 
line in (A)) whose growth was inhibited by AZD893, (D) shows resistant tumour that 
has retained the morphology of the AZD8931 naïve (vehicle) tumours an (E, F) show 
resistant tumours with a spindle cell morphology. (G-P) Immunohistochemical 
analysis of pAkt (G-K) and pMAPK (L-P) in vehicle and AZD8931 treated tumours. 
Mag x20, scale bar 50 m. 
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Fig. 6: Development of EMT in AZD8931 resistant tumours. 
Immunohistochemical analysis of E-cadherin, vimentin and HER2 in (A) vehicle and 
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(B-E) AZD8931 treated tumours. (B) Shows AZD8931 responsive tumour whose 
growth was inhibited by AZD8931, (C) shows resistant tumour that has retained the 
morphology of the AZD8931 naïve (vehicle) tumours and (D, E) show resistant 
tumours with a spindle cell morphology. Mag x20, scale bar 50 m. 
  
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
 
 
 
 
Fig. 7: Nuclear Zeb1 expression in spindle cell resistant tumours. 
Immunohistochemical analysis of Zeb1 in (A) vehicle and (B-E) AZD8931 treated 
tumours. (B) Shows AZD8931 responsive tumour whose growth was inhibited by 
AZD8931, (C) shows resistant tumour that has retained the morphology of the 
AZD8931 naïve (vehicle) tumours and (D, E) show resistant tumours with a spindle 
cell morphology. Mag x20, scale bar 50 m. 
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TRANSLATIONAL IMPACT 
Clinical issue 
HER2 (human epidermal growth factor receptor 2) gene amplification and/or protein 
overexpression occurs in around 20% of breast cancers and is associated with poor 
prognosis. Several drugs capable of specifically targeting the HER2 pathway have 
been developed for use in both early and late HER2-positive disease and have had a 
significant impact on the treatment of HER2-positive breast cancer. However both de 
novo and acquired resistance is a major clinical problem with the use of these agents. 
Preclinical studies have identified numerous mechanisms of both de novo and 
acquired resistance although their clinical validation has been more difficult. This 
reflects the inability of conventional cell based approaches to adequately model the 
complexity of the human disease. The use of genetically engineered mouse models 
driven by relevant oncogenes and/or tumour suppressors in which the histopathology 
and disease progression more faithfully recapitulates aspects of the human disease 
provides a viable option for identifying relevant mechanisms of resistance. 
 
Results 
Here the authors use a transgenic mouse model of HER2 driven breast cancer to 
investigate the mechanisms of resistance to AZD8931, a pan-HER family inhibitor 
which is in clinical development for the treatment of HER2-positive tumours. De 
novo resistance is associated with loss of the tumour suppressor PTEN while acquired 
resistance develops through two independent mechanisms. This includes a sub-set of 
tumours in which induction of epithelial-to-mesenchymal transition (EMT), where 
tumour cells lose their differentiated epithelial phenotype and acquire a more 
mesenchymal morphology, is concomitant with a loss of HER2 expression. 
Implications and future directions 
This study highlights the complexity of resistance mechanisms adopted by small 
molecule inhibitors by using a mouse transgenic model. The observation that 50% of 
resistant tumours no longer expressed high levels of membranous HER2 could have a 
significant impact on future treatments as currently secondary treatments are focused 
on alternative strategies for targeting HER2 signaling. It is rarely mandatory to re-
biopsy tumours at the time of entry into clinical trials, and patients whose tumours no 
longer express HER2 risk being exposed to the toxicity of treatments that might be 
anticipated to be ineffective. Furthermore exploiting the molecular differences in 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
resistant tumours that have undergone EMT may provide new therapeutic options. 
The data provide a strong rationale for basing therapeutic decisions on the biology of 
the individual resistant tumour, which may be very different from that of the primary 
tumour. 
